Microvascular Research 80 (2010) 10–17
Contents lists available at ScienceDirect
Microvascular Research
j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y m v r e
Regular Article
Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in
rabbit hindlimb ischemia model
Jie Li a,b, Yuquan Wei a, Kang Liu a,b, Chuang Yuan a, Yajuan Tang a, Qingli Quan a,b, Ping Chen a, Wei Wang a,b,
Huozhen Hu a,b,⁎, Li Yang a,⁎
a
b
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan, China
Laboratory of Medic-Biology and Cell-Biology, College of Life Science, Sichuan University, Sichuan, China
a r t i c l e
i n f o
Article history:
Received 17 August 2009
Revised 3 December 2009
Accepted 10 December 2009
Available online 4 January 2010
Keywords:
Basic fibroblast growth factor
Platelet-derived growth factor
Naked plasmid DNA
Therapeutic angiogenesis
Muscle regeneration
a b s t r a c t
Combinatorial strategy has been used in therapeutic angiogenesis in animal models of peripheral arterial
disease (PAD) and coronary artery disease for decades. Previous studies have shown that basic fibroblast
growth factor (FGF-2) and platelet-derived growth factor BB (PDGF-BB) proteins together establish
functional and stable vascular networks on mouse corneal and also in animal model of hindlimb ischemia.
However, the short half life of protein by single injection is not sufficient to achieve effective dosage,
repeated and prolonged injection causes systemic toxicity. Here we study the synergistic effects of FGF-2 and
PDGF-BB by intramuscular injection of naked plasmid DNA on therapeutic angiogenesis in rabbit model of
hindlimb ischemia. We found that transient delivery of FGF-2 and PDGF-BB naked DNA together resulted in
greater increases in capillary growth, collateral formation and popliteal blood flow compared with control
and single gene delivery. Our data provided novel evidence of beneficial effects of DNA-based FGF-2 and
PDFG-BB on muscle repair after ischemic injury. These findings reveal an alternative therapeutic approach in
the treatment of ischemic diseases and even in muscular disorders.
© 2010 Published by Elsevier Inc.
Introduction
Peripheral arterial disease (PAD) is an increasing health-threatening disorder, which can be caused by hypertension, hyperlipoidemia, hypercholesterolaemia, diabetes, smoking and population aging
(Selvin and Erlinger, 2004). It is associated with diminution in quality
of life, elevated risk of cardiovascular and cerebrovascular disease and
increased mortality (Selvin and Erlinger, 2004; Murabito et al., 2003).
However, interventional or surgical procedures are not available in
some conditions due to the complexity of the disease. Therapeutic
angiogenesis–artificially inducing endogenous angiogenesis and
collateralization in ischemic area by delivering therapeutic growth
factors, genes or cells–has been a promising approach for the
treatment of PAD and other ischemic diseases. However, the optimal
therapeutic approach has not been developed.
Basic fibroblast growth factor (FGF-2) is a powerful stimulator of
angiogenesis in vivo and is known to induce the proliferation,
migration and differentiation of many cell types–including endothelial cells, smooth muscle cells (SMC), pericytes and fibroblasts
(Galzie et al., 1997). The effects of FGF-2 on therapeutic angiogenesis
were confirmed in animal model of myocardium ischemia in early
1990s (Harada et al., 1994; Yanagisawa-Miwa et al., 1992). Platelet⁎ Corresponding authors. L. Yang is to be contacted at fax: +86 28 85164060. H. Hu, fax:
+86 28 85503520.
E-mail addresses: huhuozhen@163.com (H. Hu), yl_tracy@hotmail.com (L. Yang).
0026-2862/$ – see front matter © 2010 Published by Elsevier Inc.
doi:10.1016/j.mvr.2009.12.002
derived growth factor BB (PDGF-BB) is a mitogenic and chemotactic
factor for vascular smooth muscle cells (VSMC), monocytes and
granulocytes (Risau et al., 1992). A pilot study by Cao et al. (2003)
has shown that a combination therapy with recombinant proteins
PDGF-BB and FGF-2 successfully induced stable vascular networks in
mouse corneal and animal model of hindlimb ischemia. Delivery of a
single angiogenic factor is insufficient to induce functionally active
blood vessels and even cause serious complications (Carmeliet, 2000;
Celletti et al., 2001; Thurston et al., 1999). Thus, exploring a
combinatorial strategy has become the major focus of therapeutic
angiogenesis for PAD and other ischemic diseases. Positive results
have already been reported in many laboratories (Cao et al., 2003;
Asahara et al., 1995; Chen et al., 2007; Niagara et al., 2004; Shyu
et al., 2003).
Several delivery techniques have been used in therapeutic
angiogenesis. Direct administration of growth factor protein yielded
positive results (Bauters et al., 1994; Unger et al., 1994; Takeshita
et al., 1994). However, the short half life of protein is insufficient to
achieve effective dosage, repeated and prolonged injection could
cause systemic toxicity. The adenoviral vector-based delivery approach, though effective, induces cytotoxic immune reactions. Naked
DNA-based delivery system, thus, has become an alternative approach
to obviate immunological concerns associated with protein and
adenoviral vector. Interestingly, skeletal muscle has been reported
to take up and express naked plasmid DNA (Davis et al., 1993). Based
on these findings, we investigate whether intramuscular injection of
J. Li et al. / Microvascular Research 80 (2010) 10–17
naked plasmid DNA carrying PDGF-BB and FGF-2 genes can establish
stable mature vessels and improve collateral blood flow in rabbit
hindlimb ischemia model without causing side effects.
11
angiographic score was calculated for each film as the ratio of grid
intersections crossed by opacified arteries divided by the total number
of grid intersections in the medial thigh. This analysis was performed
by a single observer blinded to the treatment regimen.
Materials and methods
Histologic analysis and immunohistochemical stainings
Plasmid vectors
The plasmid vectors were constructed containing human FGF-2
(called pFGF2 below) or PDGF-BB (pPDGF) or both FGF-2 and PDGFBB (pPDGF/FGF2) gene, encoding secreted proteins. pNull is the same
backbone as the vectors above but contains no gene.
Animal model
We used a rabbit ischemic hindlimb model that has been described
previously (Takeshita et al., 1994). All protocols were approved by
Institutional Animal Care and Use Committee. A total of 50 male New
Zealand White rabbits weighing 3–3.5 kg were anesthetized with
sodium pentobarbital (40 mg/kg). Under sterile surgical conditions,
the femoral artery was completely excised from its proximal origin as
a branch of the external iliac artery to the point distally where it
bifurcates to form the saphenous and popliteal arteries. Consequently,
blood flow to the ischemic limb is dependent upon collateral vessels,
which may originate from the internal iliac artery. After removal of
the femoral artery, five different sites in adductor thigh muscle and
semimembranous muscle received direct injections with plasmid
(500 μg in 1 ml) with the use of a 1-ml syringe and a 25-gauge needle.
After gene delivery, the incision was closed in three layers. All rabbits
were closely monitored and received antibiotics.
Experimental procedures
All the rabbits were randomly divided into five groups (n = 10
each group): PBS, pNull, pPDGF, pFGF2 and pPDGF/FGF2. PBS and
pNull groups were referred as control. Gene transfer (GT) was
performed immediately after surgery (day 0). Two different time
points were chosen to evaluate the effects of growth factors on
angiogenesis and arteriogenesis. Rabbits were scheduled for euthanasia at 1 week (n = 5, each group) and 4 weeks (n = 5, each group)
after GT, with an overdose of intravenous pentobarbital and
potassium chloride. Measurements of popliteal blood flow were
performed 0, 7, 14, 21 and 28 days after surgery. Collateral development and capillary density were studied separately with angiography
and immunohistochemistry 1 and 4 weeks after GT.
Tissue specimens were obtained as transverse sections from the
adductor muscle and the semimembranous muscle of the ischemic
limb of each animal at the time of death (days 7 and 28). Muscle
samples were immersion-fixed in 4% PFA (pH 7.4) for more than 24 h,
embedded in paraffin, then cut into 5-μm-thick sections. The staining
of endothelial cells was performed using a mouse monoclonal
antibody (mAb) against CD31 (DAKO, Glostrup, Denmark; Dilution
1:50). A total of 20 different fields from the two muscles were
randomly selected, and capillary density (the capillary/muscle fiber
ratio) was measured. The pericytes and VSMCs were immunostained
with a mAb against α-smooth muscle actin (SMA; Neomarkers,
Fremont, CA, USA). Collaterals with diameter greater than 10 μm were
counted manually from 10 different fields (×20) selected from each
sample. The results were expressed as the number of collateral
arteries per field. Hematoxylin and eosin (H&E) staining was
performed for morphological analysis. The areas of normal, regeneration and necrosis were determined as percentages of the total muscle
area of the H&E staining sections and quantified using the ImageJ
software (NIH Software).
Statistical analysis
Data were presented as mean ± standard error (m ± SE). Statistical
evaluation of the results was performed using unpaired Student's ttest and one-way ANOVA for comparisons between two means. A
value of p b 0.05 was considered statistically significant.
Results
FGF2 and PDGF-BB increase collateral-dependent blood flow
At day 0, the Doppler flow signal from the popliteal artery could
not be detected immediately after surgery in most rabbits of each
group. Therefore, the blood flow in all groups was referred to as zero
(Fig. 1), indicating successful inducement of ischemia in hindlimb. The
blood flow in the popliteal artery was markedly improved in treated
groups (pPDGF/FGF2, pFGF2 and pPDGF group) on day 7 and peaked
at the end of follow-up (day 28). However, in the control groups,
Arterial blood flow measurement by Doppler ultrasound
Collateral vessel-dependent blood flow (ml/min) in the popliteal
artery of ischemic limb was measured at rest with a PHILIPS HDI 5000
Sono CT ultrasound instrument (Philips Medical Systems, the Netherlands), using a CL 15-7 transducer. Three separate measurements
were done for each rabbit, and the results were averaged.
Angiography and quantification of collateral growth
One and four weeks after GT, rabbits were reanesthetized. Contrast
medium (Omnipaque, 300 mg I/ml, 4 ml; GE, Shanghai, China) was
power-injected using an automated injector (Medrad, PA, USA) at a
rate of 2 ml/s via a 4F catheter placed above the aortic bifurcation.
Serial images were recorded at a rate of three films per second, and
the image representing the best arterial filling was chosen for analysis.
All of the above-described procedures were completed without the
use of heparin. Quantitative angiographic analysis of collateral vessel
development was performed as follows. A composite of 5 × 5 mm
grids was placed over the medial thigh area of angiogram. The
Fig. 1. Collateral artery-dependent blood flow (ml/min) at rest in the popliteal artery of
the ischemic limb measured with Doppler ultrasound. Greater blood flow was observed
in pPDGF/FGF2-treated limbs than any other groups. ⁎ p b 0.05 and ⁎⁎ p b 0.001 vs. PBS
control.
12
J. Li et al. / Microvascular Research 80 (2010) 10–17
the curves were flat and seemed to stop increasing at day 28.
Quantitatively, pPDGF/FGF2, pFGF2 and pPDGF caused 2.0-, 1.8- and
1.3-fold increases, respectively, as compared with PBS control. In
PDGF/FGF2-treated group, the increase of popliteal blood flow was
more pronounced than that in single gene-treated groups. There was
no difference between PBS and pNull control.
FGF2 and PDGF-BB enhance angiogenesis
Angiograms at two time points after GT (days 7 and 28) in all
groups were shown in Figs. 2 (a–j). For the entire femoral artery was
completely excised, collateral vessels mainly originated from the
internal iliac artery as expected. The development of collateral vessels
in pNull and PBS groups progressed slightly at day 7 after surgery. In
contrast, a remarkable rise could be noted after pPDGF/FGF2, pFGF2
or pPDGF infusion. Up to 28 days following GT, there were much more
large arteries formed in the medial thigh of ischemic hindlimb in
treated groups compared with control, distributed in a broader area of
ischemic muscles. Quantitative analysis of collateral vessel development was performed as described above. As shown in Fig. 2k, the
difference in the number of angiographically visible collateral vessels
(angiographic score) between treated and control groups was
significant 7 days after GT and further intensified at day 28, consistent
with the Doppler measurement of collateral-dependent blood flow.
Although a progressive increase in angiographic score was observed
in all groups from days 7 to 28, the increase calculated for the treated
groups was significantly higher than control (p b 0.001 in pPDGF/
FGF2, pFGF2 and pPDGF groups, 0.001 b p b 0.05 in control). In contrast
to single angiogenic factor, PDGF-BB and FGF-2 together caused
higher angiographic score at both 7 and 28 days after GT.
Stimulation of capillary, arteriolar and collateral growth
As studied in transversal CD31-immunostained histological sections of the semimembranous and adductor muscle (Figs. 3a–f), both
combinatorial and single gene treatments induced remarkable
Fig. 2. Angiograms of the experimental limbs in PBS (a, b), pNull (c, d), pPDGF (e, f), pFGF2 (g, h) or pPDFG/FGF2 (i, j) group 7 days (a, c, e, g, i) and 28 days (b, d, f, h, j) after femoral
artery excision. (k) The number of angiographically visible collateral vessels (angiographic score) was analyzed as described in Materials and methods. Values are shown as mean ±
SEM. ⁎ p b 0.05 and ⁎⁎ p b 0.001 vs. PBS control.
J. Li et al. / Microvascular Research 80 (2010) 10–17
13
Fig. 3. Immunohistochemical analysis of capillary in normal (a) and in ischemic muscle tissue treated with PBS (b), pNull (c), pPDGF (d), pFGF2 (e) or pPDFG/FGF2 (f) 7 days after
GT. Capillaries were stained positive for CD31 (brown stain) as denoted by arrows. Scale bar, 50 μm. Quantitative analysis of capillaries/myocytes ratio in ischemic hindlimb muscles
(g). ⁎p b 0.05 and ⁎⁎p b 0.001 vs. normal.
angiogenic effect 7 days after GT. The capillary density (capillary/
muscle fiber ratio) was significantly higher in all treated groups than
control and normal muscle tissue from intact limb. Especially in
pPDGF/FGF2 group, the ratio was 3.3-fold as compared to normal at
day 7, but reduced by 46.7% at day 28. The same phenomenon could
be observed in single gene-treated groups that the greatest angiogenic
effect appeared on day 7 after GT, but almost fell down to the baseline
at the end of follow-up. The ratio also increased slightly in pNull and
PBS control at day 7, but with no statistical significance (Fig. 3g). To
further validate the effect of these growth factors on stimulation of
collateral growth, we carried out immunohistochemical analysis
using an antibody against SMA (Figs. 4a–f). Collateral numbers were
measured from SMA-positive vessels (Fig. 4g). Although the SMApositive stained vessels were present in muscle tissues treated with
growth factors and control, combination of PDGF-BB and FGF-2
delivery resulted in a marked increase in the number of arterioles and
relatively large arterial vessels with thickened pericyte coverage
parallel to the angiographic analysis. However, in single gene-treated
14
J. Li et al. / Microvascular Research 80 (2010) 10–17
Fig. 4. Anti-SMA staining of histological sections of ischemic hindlimb muscle tissue treated with PBS (b), pNull (c), pPDGF (d), pFGF2 (e) or pPDFG/FGF2 (f) 28 days after GT and in
normal tissue (a). Arrows point to positive stained arterial vessels. Scale bar, 50 μm. Quantitative analysis of arterioles and large arterial vessels in ischemic limbs (g). ⁎p b 0.05 and
⁎⁎p b 0.001 vs. normal.
groups and especially in control groups, the number of SMA-positive
vessels was apparently inferior to that of pPDGF/FGF2-treated group.
These results provide compelling evidence that PDGF-BB and FGF-2
synergistically stimulated both capillary sprouting and collateral
growth which gave rise to stable arterial vascular networks, but did
not further enhance angiogenesis.
PDGF-BB and FGF-2 induce muscle regeneration
Histological analysis revealed that an enhanced regeneration was
detected in pPDGF/FGF2-treated samples after ischemic injury (Fig. 5).
The normal muscle was identified by myotubes with uniform caliber
size and peripheral nuclei with small and oral structure. The muscle
from pNull group 28 days after ischemia was characterized by
numerous necrotic fibers, infiltration of inflammatory cells and
invasion by connective tissue. Only a few regenerating fibers encircled
the residual necrotic myofibers, and a massive fiber loss with adipose
substitution was evident. In contrast, the effect on promotion of
muscle repair after damage was prominent in pPDGF/FGF2-treated
samples. The area of necrosis was significantly decreased, and
regenerating area which identified as myofibers with small size and
centrally located nuclei was predominant (Fig. 6). It is worth noticing
that the regenerating area seemed preferentially adjacent to vessels. In
addition, the nuclei in treated muscles appeared to be round and
enlarged in comparison of normal and control samples.
Discussion
Clinical trails based on single gene delivery did not yield
satisfactory results, leading to research focused on developing
combinatorial strategy in therapeutic angiogenesis, which has already
been adopted in treatment of many human diseases on animal models
with cancer, leucocythemia and ischemic diseases et al. Previously
published data have indicated that single angiogenic agent resulted in
deleterious effects. For example, VEGF overexpression led to the
formation of angioma-like fragile capillaries in animals and transient
edema in human patients (Lee et al., 2000; Schwartz et al., 2000). In
the current study, we found that the delivery of naked PDGF-BB and
FGF-2 DNA alone induced neovascularization in rabbit model with
hindlimb ischemia and the combination of both can give even better
results than single gene delivery.
It has been demonstrated that PDGF-BB and FGF-2 have stimulatory effects on endothelial cells. Histologic analysis shows that the
capillary density was remarkably increased 7 days after GT. In this
J. Li et al. / Microvascular Research 80 (2010) 10–17
15
Fig. 5. Hematoxylin and eosin-stained histological section of normal muscle and ischemic muscle treated with pPDGF/FGF2 (pP/F) and pNull 28 days after GT. The two figures in the
same row are representative images selected from the same group. An interstitial inflammatory infiltration was observed in both pNull and pPDGF/FGF2-treated muscles but not in
normal tissue. Areas of adipose substitution (asterisk) and segmental necrosis (n) were predominantly evident in pNull group. In contrast, pPDGF/FGF2 injection promoted muscle
regeneration after ischemia, with the presence of small regenerated fibers with central nucleus (arrow). Intramuscular macrophages (arrowhead) indicated the removal of the
necrotic fibers. The inserts show a 400 × original magnification of the PDGF/FGF2-treated muscle. A, artery; F, fibrosis. Scale bar, 50 μm.
Fig. 6. Quantification of normal area (a), necrotic area (b) and regenerating area (c) of muscle sections from normal, pNull and pPDGF/FGF2-treated muscles. ⁎p b 0.05 vs. pNulltreated rabbits.
16
J. Li et al. / Microvascular Research 80 (2010) 10–17
process, FGF-2 was assumed to play a critical role on the robust
angiogenic response, and up-regulated PDGFR-α and PDGFR-β which
subsequently induced potent angiogenic activity of PDGF-BB as well.
After that, the capillary density decreased and nearly declined to basal
level on day 28 in all groups except PDGF/FGF2-treated group.
However, the numbers of collateral arteries and arterioles increased
according to the information from angiography and immunostaining.
In contrast to angiogenesis, arteriogenesis needs a longer period —
several weeks. After angiogenic response, the next task was to
stabilize the newly formed vessels and remodel the vascular network.
Both blood flow and pericyte coverage are critical determinants of
vessel persistence (Benjamin et al., 1998; Sho et al., 2001). It has been
shown in the chronic myocardial infarction model that PDGF-BB
preferentially stimulates arteriolar growth (Hao et al., 2004).
Pericytes recruited by PDGF-BB is important for stabilization and
maturation of vascular structure (Darland and D'Amore, 1999). PDGFBB can also up-regulate the promoter activity of FGF receptor 1
(FGFR1) on VSMCs. Our data show that there are much more
arterioles with strengthened pericyte coverage and collateral arteries
in pPDGF/FGF2-treated muscle than control. Such increases in the
number and diameter of collaterals therefore contribute to the
tremendous augmentation in perfusion. According to Poeseuille'
law, the blood flow is related to fourth power of the vessel's radius,
which means the size of vessels is critical for the collateral blood flow.
Consequently, arteriogenesis is probably more efficient for therapeutic angiogenesis.
Our results are consistent with previous finding in mouse cornea
that PDGF-BB and FGF-2 synergistically induced establishment of
long-lasting, functional arterial vessels. Unlike repeated injections of
protein, in the present study we used one-time administration by
intramuscular injection of non-viral DNA. In our previous studies, the
treatment of PDGF/FGF2 mediated by adenoviral vector seemed to
result in better collateral development in ischemic limb than naked
DNA injection. Nonetheless, it should be noticed that adenoviral
vectors caused moderate inflammatory reaction (data not shown).
Speaking of clinical application, the use of naked DNA is safe and
convenient. Moreover, skeletal muscle seems to internalize naked
DNA more efficiently than other types of tissues (Davis et al., 1993).
We consider that the level of the secreted gene product by direct
naked DNA delivery is sufficient to achieve therapeutic angiogenesis.
Previous studies have reported that a short period of VEGF expression
was unable to support stable vessels but resulted in vessel regression
(Gounis et al., 2005). It implicates that vessel development requires
continued production of the initiating factors, unless there is a specific
combination such as PDGF-BB and FGF-2. The mechanism of how to
remodel and stabilize the newly formed vasculature after removal of
exogenous growth factors is probably due to aggregation and
autophosphorylation of PDGF receptors on endothelial and mural
cells independent of ligand (Cao et al., 2003).
Therapeutic angiogenesis has a limited time window. According to
the observation by Hoefer et al. (2001), there was no difference
between treated groups and control when the treatment was
performed 3 weeks after femoral occlusion. Once the spontaneous
development ended, a late treatment had no significant effect. This
finding reminds us that the time of delivery is important for the effect
of treatment. We have tried two time schedules of treatment in our
studies — one is to treat on day 10 after femoral incision and the other
is to treat immediately after surgery. Our results resembled their
findings that if there allowed for 10-day interval for postoperative
recovery, the results came out to be inferior to that of the treatment
performed as soon as after surgery (data not shown). The difference
caused by these two time schedules implied us the existence of a
narrow time window for responsiveness to the angiogenic actions of
PDGF-BB and FGF-2. It should be noted that rabbits have a strong
regenerative capacity to recover from ischemic injury, since the blood
flow and collateral growth also improved a lot in control groups.
When the endogenous collateral development has progressed to an
extent, the blood supply to low limb and media thigh seemed to be
sufficient, then injection of exogenous growth factors at that time
point probably have no further effect on angiogenesis or arteriogenesis. We can assume that, if a 10-day interval was allowed, a moderate
angiogenesis could be induced by exogenous growth factors in a short
time after GT. Nevertheless, such newly formed vessels were usually
small and immature that blood flow was more preferentially to go
through the existing collateral vessels developed during the 10-day
interval. Blood flow is important to vessel maintenance and growth
(Benjamin et al., 1998), the newly formed vessels therefore regressed
eventually by a pruning process to the advantage of the existing lager
ones that conduct blood more efficiently (Hoefer et al., 2001; Rissanen
et al., 2005). We also did not observe visible angiogenesis in normal
muscle injected with these growth factors. It was implicated that
ischemia is required for optimal effectiveness of angiogenesis and
arteriogenesis induced by growth factors. In a word, we conclude that
a 10-day interval between surgery and treatment may depress the
responsiveness of the angiogenic activity of PDGF-BB and FGF-2.
Ischemia can cause ischemic injury to cardiac and skeletal muscle
and eventually lead to tissue necrosis. Under normal circumstance,
adult skeletal muscle is a stable tissue, and the majority of muscle cells
are postmitotic, recognized as terminal differentiated. Muscle satellite
cell is a kind of stem cell residing beneath the basal lamina of mature
skeletal muscle fibers, quiescent most of the time (Campion, 1984).
Upon injury, skeletal muscle has a remarkable ability of regeneration,
which is initiated by the proliferation of quiescent satellite cells and
differentiation into myocytes to regenerate damaged myofibers
(Campion, 1984). However, in some pathological conditions such as
PAD patients especially those with critical limb ischemia or in the
course of normal aging associated with poor muscle regenerative
capacity, is this endogenous regeneration sufficient to prevent the loss
of muscle mass? Based on prior reports, PAD has some negative
impacts on muscle, causing alterations in fiber type distribution,
denervation and apoptosis in skeletal muscle, which will further
result in the functional impairment of muscle and exercise intolerance
(Askew et al., 2007; Mitchell et al., 2007). Our results presented here
suggest that PDGF/FGF2 not only greatly improved the perfusion of
ischemic limb, but also took effect on muscle regeneration after
ischemic injury. The exact mechanism has remained unclear. On one
hand, in vivo experiments have demonstrated that FGF-2 can activate
satellite cells (Lefaucheur and Sebille, 1995a) and it is a potent
stimulator of myoblasts proliferation and fusion in vitro (Menetrey et
al., 2000). FGF-2 plays an important role in muscle regeneration, as
delivery of this gene led to an enhancement of skeletal muscle repair
and an increase in muscle fiber density and size after injury
(Lefaucheur and Sebille, 1995a). Likewise, FGF-2-treated wounds
showed an average of 20-fold increase of regenerating myotubes
(Doukas et al., 2002). On the contrary, injection of neutralizing
antibodies of FGF-2 can inhibit muscle regeneration (Lefaucheur and
Sebille, 1995b). On the other hand, reconstruction of vascular
networks also has indirect positive impacts on ischemic tissue,
supplying abundant nutrients and oxygen for instance. Muscle
regeneration depends on oxygen, which is supported by blood
perfusion via angiogenesis and collateral formation (Yun et al.,
2005). Conversely, regenerated muscle promotes angiogenesis by
producing angiogenic factors. Muscle regeneration, angiogenesis and
collateral formation are linked and interact with each other.
In conclusion, our data imply that a short exposure of ischemic
tissue to PDGF-BB and FGF-2 is sufficient to establish stable and
functional vessels. It changes the therapeutic strategy from sustained
release of angiogenic factors to ‘one-short’ delivery, which is more
convenient and safer for clinical application. Moreover, in our
laboratory, we confirmed that PDGF-BB and FGF-2 also induce
angiogenesis and arteriogenesis in both rat models of cardiac ischemia
and cerebral ischemia. Although further studies are required for the
J. Li et al. / Microvascular Research 80 (2010) 10–17
safety of clinical trail, our findings provide an alternative strategy
for the treatment of PAD and a possible therapeutic guideline for
muscular disorder.
Acknowledgments
This work was supported by National 863 Project of China
(2007AA021202 and 2007AA021007). Ms. XR Wen (Department of
Ultrasonic diagnosis, West China Medical School) and Mr. CW Zhang
(Intervention Operating Room, West China Medical School) are
acknowledged for their expert technical help. We also thank the personnel of Experimental Animal Center at Sichuan University for expert
care of animals.
References
Asahara, T., Bauters, C., Zheng, L.P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J.F.,
Isner, J.M., 1995. Synergistic effect of vascular endothelial growth factor and basic
fibroblast growth factor on angiogenesis in vivo. Circulation 92, 365–371.
Askew, C.D., Green, S., Walker, P.J., Kerr, G.K., Green, A.A., Williams, A.D., Febbraio, M.A.,
2007. Skeletal muscle phenotype is associated with exercise tolerance in patients
with peripheral arterial disease. J. Vasc. Surg. 41, 802–807.
Bauters, C., Asahara, T., Zheng, L.P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J.F.,
Isner, J.M., 1994. Physiological assessment of augmented vascularity induced by
VEGF in ischemic rabbit hindlimb. Am. J. Physiol. 267, 1263–1271.
Benjamin, L.E., Hemo, I., Keshet, E., 1998. A plasticity window for blood vessel
remodeling is defined by pericyte coverage of the preformed endothelial network
and is regulated by PDGF-B and VEGF. Development 125, 1591–1598.
Campion, D.R., 1984. The muscle satellite cell: a review. Int. Rev. Cytol. 87, 225–251.
Cao, R.H., Brakenhielm, E., Pawliuk, R., Wariaro, D., Post, M.J., Wahlberg, E., Leboulch, P.,
Cao, Y.H., 2003. Angiogenic synergism, vascular stability and improvement of hindlimb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604–613.
Carmeliet, P., 2000. VEGF gene therapy: stimulating angiogenesis or angiomagenesis?
Nat. Med. 6, 1102–1103.
Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R., Dake, M.D., 2001.
Vascular endothelial growth factor enhances atherosclerotic plaque progression.
Nat. Med. 7, 425–429.
Chen, F., Tan, Z., Dong, C.Y., Li, X., Xie, Y., Wu, Y., Chen, X., Guo, S., 2007. Combination of
VEGF165/angiopoietin-1 gene and endothelial progenitor cells for therapeutic
neovascularization. Eur. J. Pharmacol. 568, 222–230.
Darland, D.C., D'Amore, P.A., 1999. Blood vessel maturation: vascular development
comes of age. J. Clin. Invest. 103, 157–158.
Davis, H.L., Demeneix, B.A., Quantin, B., Coulombe, J., Whalen, R.G., 1993. Plasmid DNA is
superior to viral vectors for direct gene transfer into adult mouse skeletal muscle.
Hum. Gene Ther. 4, 733–740.
Doukas, J., Blease, K., Craig, D., Ma, C., Chandler, L.A., Sosnowski, B.A., Pierce, G.F., 2002.
Delivery of FGF genes to wound repair cells enhances arteriogenesis and
myogenesis in skeletal muscle. Mol. Ther. 5, 517–527.
Galzie, Z., Kinsella, A.R., Smith, J.A., 1997. Fibroblast growth factors and their receptors.
Biochem. Cell. Biol. 75, 669–685.
Gounis, M.J., Spiga, M.G., Graham, R.M., Wilson, A., Haliko, S., Lieber, B.B., Wakhloo, A.K.,
Webster, K.A., 2005. Angiogenesis is confined to the transient period of VEGF
expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther. 12,
762–771.
Hao, X., Mansson-Broberg, A., Gustafsson, T., Grinnemo, K.H., Blomberg, P., Siddiqui, A.J.,
Wardell, E., Sylven, C., 2004. Angiogenic effects of dual gene transfer of bFGF and PDGFBB after myocardial infarction. Biochem. Biophys. Res. Commun. 315, 1058–1063.
Harada, K., Grossman, W., Friedman, M., Edelman, E.R., Prasad, P.V., Keighley, C.S.,
Manning, W.J., Sellke, F.W., Simons, M., 1994. Basic fibroblast growth factor
17
improves myocardial function in chronically ischemic porcine hearts. J. Clin. Invest.
94, 623–630.
Hoefer, I.E., Royen, N.V., Buschmann, I.R., Piek, J.J., Schaper, W., 2001. Time course of
arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc. Res. 49,
609–617.
Lee, R.J., Springer, M.L., Blanco-Bose, W.E., Shaw, R., Ursell, P.C., Blau, H.M., 2000. VEGF
gene delivery to myocardium: deleterious effects of unregulated expression.
Circulation 102, 898–901.
Lefaucheur, J.P., Sebille, A., 1995a. Basic fibroblast growth factor promotes in vivo
muscle regeneration in murine muscular dystrophy. Neurosci. Lett. 202, 121–124.
Lefaucheur, J.P., Sebille, A., 1995b. Muscle regeneration following injury can be
modified in vivo by immune neutralization of basic fibroblastic growth factor,
transforming growth factor beta-1 or insulin-like growth factor I. J. Neuroimmunol.
5, 85–91.
Menetrey, J., Kasemkijwattana, C., Day, C.S., Bosch, P., Vogt, M., Fu, F.H., Moreland, M.S.,
Huard, J., 2000. Growth factors improve muscle healing in vivo. J. Bone Joint Surg.,
Br. 82, 131–137.
Mitchell, R.G., Duscha, B.D., Robbins, J.L., Redfern, S.I., Chung, J., Bensimhon, D.R., Kraus,
W.E., Hiatt, W.R., Regensteiner, J.G., Annex, B.H., 2007. Increased levels of apoptosis
in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc.
Med. 12, 285–290.
Murabito, J.M., Evans, J.C., Larson, M.G., Nieto, K., Levy, D., Wilson, P.W.F., 2003. The
ankle-brachial index in the elderly and risk of stroke, coronary disease, and death:
the Framingham Study. Arch. Intern. Med. 163, 1939–1942.
Niagara, M.I., Haider, H.K., Ye, L., Koh, V.S., Lim, Y.T., Pho, K.K., Ge, R., Sim, E.K., 2004.
Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector
for treatment of hind limb ischemia. J. Vasc. Surg. 40, 774–785.
Risau, W., Drexler, H., Mironov, V., Smits, A., Siegbahn, A., Funa, K., Heldin, C.H., 1992.
Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7, 261–266.
Rissanen, T.T., Korpisalo, P., Markkanen, J.E., Liimatainen, T., Orden, M.R., Kholova, I.,
de Goede, A., Heikura, T., Gröhn, O.H., Ylä-Herttuala, S., Heikura, T., 2005. Blood
flow remodels growing vasculature during vascular endothelial growth factor
gene therapy and determines between capillary arterialization and sprouting
angiogenesis. Circulation 112, 3937–3946.
Schwartz, E.R., Speakman, M.T., Patterson, M., Hale, S.S., Isner, J.M., Kedes, L.H.,
Kloner, R.A., 2000. Evaluation of the effects of intramyocardial injection of DNA
expressing vascular endothelial growth factor (VEGF) in a myocardial infarction
model in the rat: angiogenesis and angioma formation. J. Am. Coll. Cardiol. 35,
1323–1330.
Selvin, E., Erlinger, T.P., 2004. Prevalence of and risk factors for peripheral arterial
disease in the United States: results from the National Health and Nutrition
Examination Survey 1999–2000. Circulation 110, 738–743.
Sho, E., Sho, M., Singh, T.M., Xu, C., Zarins, C.K., Masuda, H., 2001. Blood flow decrease
induces apoptosis of endothelial cells in previously dilated arteries resulting from
chronic high blood flow. Arterioscler. Thromb. Vasc. Biol. 21, 1139–1145.
Shyu, K.G., Chang, H., Isner, J.M., 2003. Synergistic effect of angiopoietin-1 and vascular
endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit
model with acute hindlimb ischemia. Life Sci. 73, 563–579.
Takeshita, S., Zheng, L.P., Brogi, E., Kearney, M., Pu, L.Q., Bunting, S., Ferrara, N., Symes,
J.F., Isner, J.M., 1994. Therapeutic angiogenesis: a single intraarterial bolus of
vascular endothelial growth factor augments revascularization in a rabbit ischemic
hindlimb model. J. Clin. Invest. 93, 662–670.
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T.N., Yancopoulos, G.D., McDonald,
D.M., 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511–2514.
Unger, E.F., Banai, S., Shou, M., Lazarous, D.F., Jaklitsch, M.T., Scheinowitz, M., Correa, R.,
Klingbeil, C., Epstein, S.E., 1994. Basic fibroblast growth factor enhances myocardial
collateral flow in a canine model. Am. J. Physiol. 266, 1588–1595.
Yanagisawa-Miwa, A., Uchida, Y., Nakamura, F., Tomaru, T., Kido, H., Kamijo, T.,
Sugimoto, T., Kaji, K., Utsuyama, M., Kurashima, C., Ito, H., 1992. Salvage of infarcted
myocardium by angiogenic action of basic fibroblast growth factor. Science 257,
1401–1403.
Yun, Z., Lin, Q., Giaccia, A.J., 2005. Adaptive myogenesis under hypoxia. Mol. Cell. Biol.
25, 3040–3055.